Please login to the form below

Not currently logged in
Email:
Password:

oncolytic viruses

This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via 210m ViraTherapeutics deal. Option to acquire the Austrian biotech after phase I trials remains open to Boehringer . ... The deal - valued at up to 210m ($236m) - gives Boehringer joint development rights to

Latest news

  • BMS to explore new options for its immuno-oncology drug Opdivo BMS to explore new options for its immuno-oncology drug Opdivo

    Jean Viallet, global clinical research lead for oncology at BMS, said: “ This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    The FDA has approved Amgen's Imlygic for melanoma, the first oncolytic virus therapy to get a green light in the US. ... Amgen is also looking at combining the oncolytic virus therapy with Merck &Co's checkpoint inhibitor Keytruda (pembrolizumab) in head

  • MedImmune partners with US National Cancer Institute MedImmune partners with US National Cancer Institute

    The deal follows the news earlier this month that MedImmune has formed a partnership with Omnis Pharmaceuticals to develop oncolytic viruses - viruses that are designed to infect and kill cancer cells -

  • MedImmune partners with US National Cancer Institute MedImmune partners with US National Cancer Institute

    The deal follows the news earlier this month that MedImmune has formed a partnership with Omnis Pharmaceuticals to develop oncolytic viruses - viruses that are designed to infect and kill cancer cells -

  • AZ signs yet another cancer immunotherapy deal AZ signs yet another cancer immunotherapy deal

    The two companies with work together to develop oncolytic viruses - viruses that are designed to infect and kill cancer cells. ... The potential for oncolytic viruses as cancer treatments has been known for several decades although it is only in the past

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still

  • Deal Watch December 2016 Deal Watch December 2016

    995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “ armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.

  • The Maverick: giving medicines away free The Maverick: giving medicines away free

    His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Turnstone Biologics bolsters leadership team Turnstone Biologics bolsters leadership team

    Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics